1-苄基-4-羟基吡咯烷-2-酮 | 125370-52-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-苄基-4-羟基吡咯烷-2-酮
• 英文名称: 4-hydroxy-N-benzylpyrrolidin-2-one
• 英文别名: (±)-1-benzyl-4-hydroxypyrrolidin-2-one；1-Benzyl-4-hydroxypyrrolidin-2-one
• CAS: 125370-52-7
• 化学式: C₁₁H₁₃NO₂
• 分子量: 191.23
• InChiKey: OGAWUYQBXWYIJM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  40.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-苄基-4-羟基吡咯烷-2-酮 生成 N-苄基-3-吡咯烷醇
  参考文献：
  名称：

  IRIUTIDZIMA, SINOBU;MASUDA, TAKAXITO

  摘要：

  DOI：
• 作为产物：
  描述：

  (E)-methyl-4-(N-benzylamino)-but-2-enoate 在 双氧水 、 potassium carbonate 、 sodium hydroxide 、 copper(ll) bromide 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 26.17h， 生成 1-苄基-4-羟基吡咯烷-2-酮
  参考文献：
  名称：

  硼酸酯γ-内酰胺结构单元的合成

  摘要：

  饱和杂环广泛存在于生物活性化合物（例如药物和农用化学品）中。但是，用于这些结构的源自硼酸的构建基块的可用性有限，特别是与杂芳族硼酸相比。我们报告了通过Cu催化的共轭硼酸酯化环化方案制备硼酸酯γ-内酰胺。使用手性催化剂，这可以高对映选择性进行。对这些试剂的进一步转化的探索表明，硼酸酯作为化学基础材料具有很大的潜力。

  DOI：

  10.1002/adsc.202001339

文献信息

• Photolysis of olefinic N-chloropyrrolidinones, N-chlorosuccinimides and N-chloro-oxazolidinones: Reactivity of cyclic carboxamidyl, imidyl and carbamyl radicals in intramolecular reactions
  作者：Benoit Daoust、Jean Lessard

  DOI：10.1016/s0040-4020(98)01158-2

  日期：1999.3

  carboxamidyl, imidyl and carbamyl radicals constrained to undergo intramolecular reactions uniquely via their planar or slightly twisted (30–35°) ΠN state (1,5-transfer of an allylic hydrogen, 5-exo or 6-exo cyclization to give bicyclo[2.2.1]azaheptane and bicyclo[3.2.1]azaoctane skeletons respectively), those intramolecular reactions being unaccessible to the planar ΣN state. Their photolysis gave products

  制备N-氯-烯基吡咯烷酮，N-氯-烯基琥珀酰亚胺和N-氯-烯基恶唑烷酮作为烯属环羧酰胺基，亚胺基和氨基甲酸酯基团的前体，这些化合物仅通过它们的平面或轻微扭曲（30-35°）π分子内发生反应。N状态（烯丙基氢的1,5-转移，5- exo或6- exo环化分别产生双环[2.2.1]氮杂庚烷和双环[3.2.1]氮杂辛烷骨架），这些分子内反应是平面无法获得的Σ ñ状态。他们的光解作用产生的产物独特地是由这些氮自由基的分子间反应产生的（添加到外部烯烃中，从溶剂中提取氢，烯丙基氢提取）。用N-氯-链烯基吡咯烷酮和N-氯-链烯基恶唑烷酮，观察到通过5-外显环化反应生成双环[3.3.0]氮杂辛烷衍生物的分子内反应。在这两种情况下，无论是Π Ñ和Σ Ñ环状酰胺基自由基的状态允许5 -外环化轨道重叠。
• [EN] PYRROLIDINE AND BICYCLOHETEROARYL CONTAINING OGA INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS D'OGA CONTENANT DE LA PYRROLIDINE ET DE LA BICYCLOHÉTÉROARYLE
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2021094312A1

  公开（公告）日：2021-05-20

  The present invention relates to O-GIcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.

  本发明涉及O-GIcNAc水解酶（OGA）抑制剂。该发明还涉及包含这类化合物的药物组合物，制备这类化合物和组合物的方法，以及利用这类化合物和组合物预防和治疗抑制OGA有益的疾病，如tau病变，特别是阿尔茨海默病或进行性上行性麻痹；以及伴有tau病理的神经退行性疾病，特别是由C90RF72突变引起的肌萎缩侧索硬化或额颞叶痴呆；或α-突触核蛋白病，特别是帕金森病，由帕金森病引起的痴呆（或由帕金森病引起的神经认知障碍），具有Lewy小体的痴呆，多系统萎缩，或由高雪氏病引起的α-突触核蛋白病。
• Process for preparing optically active 4-hydroxy-2-pyrrolidinone and n-substituted 4-hydroxy-2-pyrrolidinones by enzymatic hydroxylation
  申请人：——

  公开号：US20040009562A1

  公开（公告）日：2004-01-15

  This invention provides a process for the preparation of optically active 4-hydroxy-2-pyrrolidinone or N-substituted 4-hydroxy-2-pyrrolidinones, wherein an oxygen atom is inserted regio- and stereoselectively into the corresponding non-hydroxylated 2-pyrrolidinones, by using, as a biocatalyst, a microorganism having hydroxylation activity, or a host-organism having the gene(s) necessary for the hydroxylation enzymes derived from the said microorganism, or an enzyme having hydroxylation activity derived from the above microorganisms. The microorganism may be selected from the group consisting of microorganisms that degrade alkanes or cyclic hydrocarbons, microorganisms having alkane hydroxylase(s), or microorganisms that are able to oxidize hydrocarbons.

  本发明提供了一种制备光学活性4-羟基-2-吡咯烷酮或N-取代的4-羟基-2-吡咯烷酮的方法，其中将氧原子以区域和立体选择性插入相应的非羟基化2-吡咯烷酮中，使用具有羟化活性的微生物或具有来自所述微生物的羟化酶所必需的基因的宿主生物作为生物催化剂，或者使用来自上述微生物的羟化酶活性的酶。微生物可以从降解烷烃或环烃的微生物、具有烷烃羟化酶的微生物或能够氧化碳氢化合物的微生物中选择。
• Process for the preparation of oxazolidinones and method of use thereof
  申请人：Hollingsworth I. Rawle

  公开号：US20070265451A1

  公开（公告）日：2007-11-15

  A process for preparing N-(substituted)-C-(substituted methyl)-oxazolidinones, C-(substituted methyl)-oxazolidinones, and N-(substituted)-C-(substituted methyl)-oxazolidinones, preferably chiral, from optically active C-(protected oxymethyl)-oxazolidinones is described. The process can be used to produce combinatorial libraries of the above substituted oxazolidinones in a two or three step reaction comprising a plurality of reagents differing in numbers of carbons or particular substituted oxazolidinones. A number of substituted oxazolidinones produced using the above process have been discovered to have antimicrobial activity.

  本文介绍了一种从光学活性的C-（保护的氧甲基）-噁唑烷酮制备N-（取代）-C-（取代甲基）-噁唑烷酮、C-（取代甲基）-噁唑烷酮和N-（取代）-C-（取代甲基）-噁唑烷酮的方法，其中优选手性化合物。该方法可用于在包含多种碳数或特定取代噁唑烷酮的多种试剂的两步或三步反应中产生上述取代噁唑烷酮的组合库。使用上述方法生产的许多取代噁唑烷酮已被发现具有抗微生物活性。
• PROCESS FOR THE PREPARATION OF OXAZOLIDINONES AND METHOD OF USE THEREOF
  申请人：Hollingsworth Rawle I.

  公开号：US20080146458A1

  公开（公告）日：2008-06-19

  Substituted oxazolidinone of the formula: wherein R 2 is alkyl selected from the group consisting of methyl, ethyl, and isopropyl moieties, are described. The compounds are antibacterial.

  描述了以下化学式的氧杂环丙酮类替代物：其中R2是选择自甲基，乙基和异丙基基团的烷基。这些化合物具有抗菌作用。